Source: Siyu MedTech; Editor: Sophia
Reprint requirements: Can be reprinted 24 hours after the first publication, source must be credited.
August 7, 2024Abbott and Medtronic Announce Major Partnership in Diabetes Technology FieldThe two companies will integrate Abbott's CGM (Continuous Glucose Monitoring) products with Medtronic's insulin delivery systems through this collaboration. According to the agreement, Abbott will be responsible for developing the sensors, while Medtronic will handle sales.The two companies have not yet disclosed specific details such as the financial terms of the partnership.In addition, Medtronic's Simplera CGM also received FDA approval in the United States on August 7.Left: Abbott FreeStyle Libre 3 CGM Right: Medtronic MiniMed 780GThis collaboration aims to bring Abbott'sFreeStyle Libre CGM （FreeStyle Libre 3) Products and Medtronic's automatic insulin pump (MiniMed 780G）and smart insulin pen （InPen System) are integrated to jointly develop a comprehensive system.The combination of Abbott's CGM with Medtronic's automated insulin delivery algorithm will enable automatic adjustment of insulin.Ensure blood glucose remains within the ideal range.- Abbott Continuous Glucose Monitoring Technology:FreeStyle Libre 3
FreeStyle Libre 3 It is a continuous glucose monitoring (CGM) system, an upgrade from the 2nd generation.Total volume reduced by 70%, with a 14-day usage cycle, high precision, and selectable high and low blood glucose alarms.At the same time, this product also developed a smartphone application that automatically receives real-time blood glucose data via Bluetooth. It can directly provide continuous and real-time glucose readings to smartphones and is suitable for diabetic patients aged 4 years and above.Abbott has reached cooperation with multiple insulin pump manufacturers. Libre can now connect to automated insulin delivery pumps, such as Tandem's t:slim X2 pump. FreeStyle Libre 2 can be integrated with Insulet's Omnipod 5.
- Medtronic's New Generation Automated Insulin Delivery Technology: MiniMed 780G
MiniMed™ 780G is Medtronic's most advanced insulin delivery system,Adopting SmartGuard technology,Automatically adjusts insulin delivery every 5 minutes,Can automatically predict and keep blood glucose levels within the normal range.The default target blood glucose range for the product is set to 120mg/dL, butCan be adjusted to 110 or 100 mg/dL;In addition, the system features Meal Detection™ functionality, which can effectively prevent post-meal hyperglycemia when users occasionally forget.
- MedtronicInPen™ Smart Insulin Pen
InPen™ is a reusable smart insulin pen that uses Bluetooth technology to send dose information to a mobile application.InPen provides dose calculation and tracking functions, helping patients save some mental arithmetic work in diabetes management.Medtronic has been using its own CGMs, such as the Guardian 4 and Simplera platforms, and plans to continue incorporating these systems as part of its CGM portfolio.Jared Watkin, Executive Vice President of Abbott's Diabetes Care Division, stated:"Abbott's FreeStyle Libre technology sets the standard for accurate, accessible, easy-to-use, and reliable continuous glucose monitoring. Integrating this CGM, built for Medtronic's insulin delivery systems and algorithms,Patients may have the opportunity to reduce the burden of managing their condition and have more time to enjoy life.”Medtronic Diabetes Executive Vice President and President Que Dallara stated:"Our collaboration with Abbott will further expand the application of automated insulin delivery systems and smart multiple daily injection (MDI) systems, allowing more people in need to benefit from intelligent technology."# MedtronicSimplera CGM Approved by FDAMedtronic's first disposable all-in-one CGM is half the size of its previous CGM. The latest fingerstick-free sensor simplifies the insertion and wearing process, eliminating the need for a belt.- Simplera CGM adopts the latest design, requires no tape, no charging, and is smaller in size, making it very easy to wear;
- Seamlessly integrated with the InPen smart insulin pen, it enables real-time, personalized dosing guidance, simplifying diabetes management. This feature received the EU CE mark in September 2023.
- Can also be used in conjunction with the Simplera Sync, which integrates with the MiniMed 780G automated insulin delivery system;
- Very convenient for diabetic patients to use, and can be used for multiple daily injections.
BTIG analysts Marie Thibault and Sam Eiber said that the cooperation news was unexpected, butThis move helps both parties expand the diabetes market while maintaining a "co-opetition" relationship.The CGM system developed in this cooperation is only compatible with Medtronic devices.The new system is unlikely to receive FDA approval or CE certification within Medtronic's current fiscal year (ending May 2025). The earliest this could happen is by the end of the 2026 fiscal year, which should be a "win-win" situation for both companies.Overall, this collaboration benefits both companies as it helps expand their respective user bases while offering patients a wider range of device options.Medtronic's move helps retain its existing user base (approximately 700,000 globally) and attract new users who have been conservative about adopting the company’s CGM system.Analysts also mentioned,For Insulet, the possibility of its Omnipod patch pump being significantly threatened is relatively low.Due to differences in product form and business model, patients who prefer tubing pumps are unlikely to switch to Insulet's Omnipod 5 patch pump, and vice versa.Investors reacted positively to the collaboration between Abbott and Medtronic, with both companies' shares slightly rising at Wednesday's close.However, other companiesStock priceThen there isDifferent degrees ofDecline: Tandem Diabetes Care closed down nearly 15%, Dexcom fell about 8%; Insulet dropped 3%.What waves will Medtronic and Abbott stir up in the diabetes care field? Siyu will continue to follow up.
Editor-in-Chief | Zhao Qing Reviewed by | Yi He
